[Medical treatment of intracranial arterial stenosis. Are primary and secondary prevention the same thing?]
Related Experiment Video
Updated: Aug 6, 2026

Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms
Published on: August 11, 2015
P Irimia-Sieira1, M Riverol-Fernández, E Martínez-Vila
1Departamento de Neurología, Clinica Universitaria de Navarra, Pamplona, España. pirimia@unav.es
Insights
Controlling vascular risk factors and using statins are crucial for treating intracranial stenosis (ICS). Further research is needed to determine the optimal antithrombotic drug for secondary prevention of stroke in these patients.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Vascular Surgery
Context:
- Atherosclerosis, a leading cause of stroke, involves atheroma plaque formation and progression.
- Intracranial atheromatosis can lead to severe cerebral ischemia.
- Effective management strategies for intracranial stenosis (ICS) are critical for preventing cerebrovascular events.
Purpose:
- To review risk factors for atheroma plaque formation and progression.
- To elucidate the mechanisms of cerebral ischemia secondary to intracranial atheromatosis.
- To discuss current and future medical treatments for primary and secondary prevention of stroke in ICS patients.
Summary:
- Medical treatment for ICS focuses on halting plaque progression and preventing recurrence.
- Key interventions include managing vascular risk factors, statin therapy, and antithrombotic agents (antiplatelet or anticoagulation).
- While antiplatelets are recommended for secondary prevention of non-cardioembolic stroke, evidence suggests oral anticoagulation may be superior; ongoing trials will clarify optimal treatment.
Impact:
- Establishes the importance of risk factor control and statins in managing ICS.
- Highlights the need for further research to define the first-line antithrombotic therapy for secondary stroke prevention in ICS.
- Aims to improve patient outcomes by optimizing medical management of intracranial atherosclerosis.
Aims:
In this study we review the risk factors associated with the formation and progression of an atheroma plaque, the mechanism involved in cerebral ischemia secondary to intracranial atheromatosis and possible medical treatment in primary and secondary prevention.
Development:
Medical treatment of intracranial stenoses (ICS) is aimed at stopping the progression of the atheroma plaque and at preventing recurrences in the case of symptomatic stenoses. It is based on the control of vascular risk factors, the use of statins and antithrombotic therapy (antiplatelet or anticoagulation drugs). Although antiplatelet agents have not proved to be beneficial in the primary prevention of stroke, they are recommended in patients with ICS in order to lower the risk of heart attack associated with this pathology. The use of antiplatelet drugs in the secondary prevention of ischemic stroke secondary to an ICS is based on clinical trials which have shown that antiaggregation prevents non-cardioembolic strokes. Nevertheless, several retrospective studies have observed that oral anticoagulation is better than antiaggregation with aspirin. Two prospective clinical trials are currently being conducted which will, in the next few years, help to determine what the first choice medical treatment is for this group of patients.
Conclusions:
Medical treatment of ICS patients must include the control of vascular risk factors and the use of statins. New studies are needed to be able to establish the first choice antithrombotic drug in secondary prevention.
Related Concept Videos
Preventive Healthcare Services
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Peripheral Artery Disease III: Interprofessional Care
Aneurysm III: Interprofessional Care

